A sulfonyl fluoride derivative inhibits EGFRL858R/T790M/C797S by covalent modification of the catalytic lysine
F Ferlenghi, L Scalvini, F Vacondio, R Castelli… - European Journal of …, 2021 - Elsevier
The emergence of the C797S mutation in EGFR is a frequent mechanism of resistance to
osimertinib in the treatment of non-small cell lung cancer (NSCLC). In the present work, we …
osimertinib in the treatment of non-small cell lung cancer (NSCLC). In the present work, we …
A sulfonyl fluoride derivative inhibits EGFR L858R/T790M/C797S by covalent modification of the catalytic lysine
F Ferlenghi, L Scalvini, F Vacondio, R Castelli… - EUROPEAN JOURNAL …, 2021 - air.unipr.it
The emergence of the C797S mutation in EGFR is a frequent mechanism of resistance to
osimertinib in the treatment of non-small cell lung cancer (NSCLC). In the present work, we …
osimertinib in the treatment of non-small cell lung cancer (NSCLC). In the present work, we …
A sulfonyl fluoride derivative inhibits EGFRL858R/T790M/C797S by covalent modification of the catalytic lysine.
F Ferlenghi, L Scalvini, F Vacondio… - European Journal of …, 2021 - europepmc.org
The emergence of the C797S mutation in EGFR is a frequent mechanism of resistance to
osimertinib in the treatment of non-small cell lung cancer (NSCLC). In the present work, we …
osimertinib in the treatment of non-small cell lung cancer (NSCLC). In the present work, we …
A sulfonyl fluoride derivative inhibits EGFRL858R/T790M/C797S by covalent modification of the catalytic lysine
F Ferlenghi, L Scalvini, F Vacondio… - European journal …, 2021 - pubmed.ncbi.nlm.nih.gov
The emergence of the C797S mutation in EGFR is a frequent mechanism of resistance to
osimertinib in the treatment of non-small cell lung cancer (NSCLC). In the present work, we …
osimertinib in the treatment of non-small cell lung cancer (NSCLC). In the present work, we …